stockrowANI Pharmaceuticals, Inc.
ANIP Healthcare Drug Manufacturers Specialty & Generic
ANI Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $883.4 million, up 43.8% from fiscal 2024.
- Revenue
- +27.6%
- EPS
- +29.4%
- Free cash flow
- +85.5%
- Total debt
- −96.2%
Quarter to September 2026, against a year earlier
Follow ANIP
Alert me
ANI Pharmaceuticals, Inc. (ANIP) EV/Sales
As of 5 November 2026, ANI Pharmaceuticals, Inc. (ANIP) trades at a EV/Sales of 1.6×. Over the past ten years it has ranged from 1.6× (November 2026) to 12.7× (March 2015) — the current reading is the lowest in ten years. That is below the Drug Manufacturers Specialty & Generic industry median of 2.9× and below the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 2.2× | (14.00%) |
| FY2024 | 2.5× | 11.60% |
| FY2023 | 2.2× | (19.60%) |
| FY2022 | 2.8× | (21.29%) |
| FY2021 | 3.6× | 40.94% |
| FY2020 | 2.5× | (39.04%) |
| FY2019 | 4.1× | 50.59% |
| FY2018 | 2.7× | (49.65%) |
| FY2017 | 5.5× | (11.75%) |
| FY2016 | 6.2× | (0.09%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 1.6× | (18.76%) |
| Jun 2026 | 2.0× | (1.10%) |
| Mar 2026 | 2.1× | (4.84%) |
| Dec 2025 | 2.2× | (18.48%) |
| 43 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| PRGO Perrigo Company plc compare | 1.2× |
| PAHC Phibro Animal Health Corporation compare | 1.4× |
| ANIP ANI Pharmaceuticals, Inc. | 1.6× |
| PCRX Pacira BioSciences, Inc. compare | 2.3× |
| BCRX BioCryst Pharmaceuticals, Inc. compare | 2.5× |
| CRON Cronos Group Inc. compare | 3.0× |
| XERS Xeris Biopharma Holdings, Inc. compare | 6.7× |
| ALVO Alvotech compare | 8.6× |
| ETON Eton Pharmaceuticals, Inc. compare | 9.4× |
| Drug Manufacturers Specialty & Generic industry median | 2.9× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)